Kaiser Jacqueline, Risteska Alana, Muller Abbey G, Sun Haoxiong, Lei Bethany, Nay Kevin, Means Anthony R, Cousin Margot A, Drewry David H, Oakhill Jonathan S, Kemp Bruce E, Hannan Anthony J, Berk Michael, Febbraio Mark A, Gundlach Andrew L, Hill-Yardin Elisa L, Scott John W
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia; St. Vincent's Institute of Medical Research, Melbourne, Victoria, Australia; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia.
Biol Psychiatry. 2025 Mar 1;97(5):439-449. doi: 10.1016/j.biopsych.2024.10.012. Epub 2024 Oct 21.
Although the precise underlying cause(s) of autism spectrum disorder remain unclear, more than 1000 rare genetic variations are associated with the condition. For many people living with profound autism, this genetic heterogeneity has impeded the identification of common biological targets for therapy development for core and comorbid traits that include significant impairments in social communication and repetitive and restricted behaviors. A substantial number of genes associated with autism encode proteins involved in signal transduction and synaptic transmission that are critical for brain development and function. CAMK4 is an emerging risk gene for autism spectrum disorder that encodes the CaMK4 (calcium/calmodulin-dependent protein kinase 4) enzyme. CaMK4 is a key component of a Ca-activated signaling pathway that regulates neurodevelopment and synaptic plasticity. In this review, we discuss 3 genetic variants of CAMK4 found in individuals with hyperkinetic movement disorder and comorbid neurological symptoms including autism spectrum disorder that are likely pathogenic with monogenic effect. We also comment on 4 other genetic variations in CAMK4 that show associations with autism spectrum disorder, as well as 12 examples of autism-associated variations in other genes that impact CaMK4 signaling pathways. Finally, we highlight 3 environmental risk factors that impact CaMK4 signaling based on studies of preclinical models of autism and/or clinical cohorts. Overall, we review molecular, genetic, physiological, and environmental evidence that suggest that defects in the CaMK4 signaling pathway may play an important role in a common autism pathogenesis network across numerous patient groups, and we propose CaMK4 as a potential therapeutic target.
尽管自闭症谱系障碍的确切潜在病因仍不明确,但有1000多种罕见的基因变异与该疾病相关。对于许多患有重度自闭症的人来说,这种基因异质性阻碍了针对核心和共病特征(包括社交沟通严重受损以及重复和受限行为)开发治疗方法时确定常见的生物学靶点。大量与自闭症相关的基因编码参与信号转导和突触传递的蛋白质,这些蛋白质对大脑发育和功能至关重要。CAMK4是自闭症谱系障碍中一个新出现的风险基因,它编码CaMK4(钙/钙调蛋白依赖性蛋白激酶4)酶。CaMK4是钙激活信号通路的关键组成部分,该信号通路调节神经发育和突触可塑性。在这篇综述中,我们讨论了在患有多动障碍和包括自闭症谱系障碍在内的共病神经症状的个体中发现的3种CAMK4基因变异,这些变异可能具有单基因效应的致病性。我们还评论了CAMK4的其他4种与自闭症谱系障碍相关的基因变异,以及其他影响CaMK4信号通路的基因中12个与自闭症相关的变异实例。最后,基于对自闭症临床前模型和/或临床队列的研究,我们强调了3种影响CaMK4信号通路的环境风险因素。总体而言,我们回顾了分子、遗传、生理和环境方面的证据,这些证据表明CaMK4信号通路的缺陷可能在众多患者群体的常见自闭症发病机制网络中起重要作用,并且我们提出CaMK4作为一个潜在的治疗靶点。